title: [Menopausal hormonal therapy and cancer risks].
abstract: Estrogen-progestagen menopausal hormonal therapy (MHT) is recognized as carcinogenic to humans. The article presents the associations between MHT and breast, ovary and endometrial cancer risks, in particular according to treatment modalities. If MHT must be prescribed, it is recommended to use the lowest dose for the shortest possible duration. Discussing with the patient the benefits but also the risks and making regular gynecological follow-up are strongly encouraged.
authors.affiliation: Département de prévention, pôle santé publique et soins, institut national du cancer, 52, avenue André-Morizet, 92100 Boulogne-Billancourt, France. Electronic address: alasserre@institutcancer.fr.
authors.forename: A
authors.initials: A
authors.lastname: Lasserre
authors.affiliation: Inserm, centre de recherche en épidémiologie et santé de populations (CESP), U1018, équipe nutrition, hormones et santé des femmes, 94805 Villejuif, France; UMRS 1018, université Paris-Sud, 94805 Villejuif, France.
authors.forename: A
authors.initials: A
authors.lastname: Fournier
mesh_terms: D001943:Breast Neoplasms / Q000453:epidemiology; D016889:Endometrial Neoplasms / Q000453:epidemiology; D015914:Estrogen Replacement Therapy / Q000009:adverse effects* / Q000379:methods; D005260:Female; D006801:Humans; D008593:Menopause; D009369:Neoplasms / Q000453:epidemiology*; D010051:Ovarian Neoplasms / Q000453:epidemiology; D011372:Progestins / Q000008:administration & dosage / Q000009:adverse effects; D012307:Risk Factors; D013997:Time Factors
chemical_list: D011372:Progestins
keywords: Breast; Cancer; Endometrium; Endomètre; Menopausal hormone therapy; Ovaire; Ovary; Sein; Traitements hormonaux de la ménopause